UMN Pharma Inc. announced today that its board resolved to enter into an agreement with ILDONG Pharmaceutical Co., Ltd., on December 28, 2012, for co-development and exclusive commercialization of recombinant influenza HA vaccines, UMN-0502, UMN-0501 and UMN-0901 in the Republic of Korea.